Victoria Johnson

Justin Riley Lam, MD, discussed findings from a retrospective cohort analysis at the 2025 ACP Internal Medicine Meeting.

Angel Goenawan, MD, shared findings from a meta-analysis of surgical and nonsurgical clinical trials.

Nawsabah Noor, MBBS, discussed how her team developed novel AI training to reduce racial bias in diagnosing mpox lesions.

Valerie Louis outlined her ASKmeGOC study and the electronic tool her team developed to help preemptively record preferences.

Zehavi Horowitz-Kugler, MD, and Ran Shaul discussed an AI model K Health developed and evaluated in a virtual urgent care clinic.

Adrienne Poon, MD, MPH, discussed early findings from a community health needs survey of AAPI populations.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

Statistically significant improvements were seen in BAS, MFI, SF-36 subscores, SSS fatigue, disrupted sleep. PEM, and orthostatic intolerance.

Patients switching to tirzepatide had greater improvements in HBA1C and weight at week 40 in a phase 4 RCT.

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Data from the phase 3 ATLAS trial supported Qfitlia's BLA, with the latest data presented at December’s ASH meeting.

Treprostinil (YUTREPIA) was previously granted tentative approval on August 16, 2024.

FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

By year 5, COPD exacerbations occurred in 81.3% of the PPV23 group and 23.6% of the PCV13 group.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

Omalizumab-igec is approved in 2 formulations for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and CSU.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

Findings were presented from the AROMA registry study in 3 abstracts at the AAAAI,WAO Joint Congress.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.

Pongdee discussed research presented at the AAAAI/WAO Joint Congress that focused on improving diagnosis of indolent systemic mastocytosis.

Subgroup analyses of the real-world REALITI-A study were presented at the 2025 AAAAI/WAO Joint Congress.

Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.